Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study.
OBJECTIVE
Evaluation of the effectiveness, safety and tolerability of gatifloxacin in the treatment of outpatients with community-acquired pneumonia (CAP).


METHODS
A prospective, multicenter, non-comparative clinical study carried out in Brazil. Voluntary, unpaid physician participation contributed to an unbiased study design.


METHODS
Adult outpatients with clinical diagnosis of CAP. REGIMEN: Gatifloxacin, 400 mg PO once daily for 7 to 14 days. STUDY PROCEDURES: Initial clinical assessment, at the first day of gatifloxacin therapy; final evaluation after 7 to 14 days of treatment.


RESULTS
According to the physicians assessments 97.3% of patients were cured or improved after gatifloxacin treatment. The incidence of adverse events was low and the most commonly reported events were nausea and dyspepsia.


CONCLUSIONS
Gatifloxacin, 400 mg PO once daily for 7 to 14 days, is effective and safe in the treatment of patients with CAP.
Franca
Suelene Aires
SA
Pulmonary Division, Clinical Hospital of Medicine School of São Paulo University, São Paulo, Brazil.
Carvalho
Carlos Roberto Ribeiro
CR
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001938:Brazil; D002493:Central Nervous System Diseases / Q000139:chemically induced; D017714:Community-Acquired Infections / Q000188:drug therapy*; D005260:Female; D024841:Fluoroquinolones; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D000077734:Gatifloxacin; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D000077734:Gatifloxacin